Marc_ Posted September 5, 2017 Endlich mal wieder brauchbare Ergebnisse aus der MS Forschung.... ...Phase III trial for the company’s lead product, Glatiramer Acetate (Copaxone®) Depot, or GA Depot, for the treatment of multiple sclerosis (MS). Mapi Pharma recently completed a successful Phase II, open-label, two arm, multicenter, study to assess safety, tolerability, and efficacy of once-a-month, long-acting IM (intramuscular) injection of 80mg or 40mg glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS)... http://www.mapi-pharma.com/mapi-pharma-ltd-announces-closing-of-10-million-investment/ ..dann gibt's demnächst Copaxone als monatliche Fertigspritze.. Share this post Link to post Share on other sites
gabih Posted September 5, 2017 wäre echt toll ..... Share this post Link to post Share on other sites
SilkeL Posted September 21, 2017 Hallo Zusammen, Hört sich echt gut an. Gruß Silke Share this post Link to post Share on other sites
Tina- Posted September 21, 2017 Mich wundert allerdings die geringe Dosierung, selbst bei intramuskulärer Injektion. Share this post Link to post Share on other sites